---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009047"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:06:16.104972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports FY2023 net loss of $29.8M; cash runway into Q4 2024

## Summary
- Net loss $29.8M for fiscal year ended Dec 31, 2023; no revenue reported (pre-revenue biotech).
- R&D expenses $19.5M, up $0.5M YoY driven by $1.5M WPD sublicense termination; G&A $10.0M, down $1.5M.
- Cash and equivalents $23.6M at year-end; management expects runway into Q4 2024.
- Closed $4.5M registered direct offering and private placement with institutional investor and insiders.
- Positive interim Annamycin data in AML; plans to advance into pivotal Phase 2B/3 trial in 2024.

## SEC filing metadata
- accession: 0001437749-24-009047
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/0001437749-24-009047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/mbrx20240321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009047
- JSON: https://secwatch.observer/filing/0001437749-24-009047.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009047.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: $29.8 million
  - Result: reported results
  source text: Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009047/0001437749-24-009047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.